- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
More ▼
Key statistics
On Friday, Akari Therapeutics PLC (AKTX:NAQ) closed at 2.23, 106.97% above the 52 week low of 1.08 set on Apr 17, 2024.
52-week range
Open | 2.15 |
---|---|
High | 2.36 |
Low | 2.13 |
Bid | 2.23 |
Offer | 2.44 |
Previous close | 2.19 |
Average volume | 22.97k |
---|---|
Shares outstanding | 396.18k |
Free float | 330.01k |
P/E (TTM) | -- |
Market cap | 15.29m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 07 2024 20:59 BST.
More ▼